Drugs / MEDI7219
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03362593 | Dec 2017 → May 2020 | — | MedImmune LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI7219 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03362593 ↗ |
| Known as | MEDI-7219 (GLP-1 RECEPTOR AGONIST) | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068617 ↗ |
| Action | Activate | “a glucagon-like peptide-1 (GLP-1) receptor agonist” PMID 40370985 ↗ Apr 2025 |
| Modality | Protein / enzyme biologic | — CHEMBL6068617 ↗ |
| Route | Oral | “oral formulation” NCT03362593 ↗ |